Joan Koerber-Walker

Life Science Investor and Managing Member at White Hat Heath Ventures LLC

[Joan Koerber-Walker @JKWinnovation]

Innovators understand that sometimes you need to color outside the lines. -- JKW

[Joan Koerber-Walker @JKWinnovation]

Expect the unexpected... Watch for it!
Get insights from 3 highly experienced life science PR professionals and former journalists. Watch the full video at https://t.co/pZcI0KPiEI
Thx @AmandaVega, @pharmaprodigy +@StacySullivan for joining @AZBioCEO on @AZBio PEERS

[Biotechnology Innovation Organization @IAmBiotech]

BIO’s Putting Americans First series shows how U.S. biotech delivers faster, broader access to lifesaving treatments than anywhere else in the world. It also uncovers the real drivers of medicine costs and why subjecting world-renowned U.S. innovations to international price setting would:
🚨 Stall critical R&D and slow lifesaving progress.
🚨 Undercut our national security.
🚨 Weaken the American workforce and slow job growth.
🚨 Diminish hope for millions of patients and families.
Get the facts: https://t.co/rJ2kHOjgA1

[Joan Koerber-Walker @JKWinnovation]

Join me at 2025's biggest celebration of health innovation, the AZBio Awards. Connect with Arizona's Bioscience Community. You'll be glad you did! https://t.co/RM0xXGFHmw

[AdvaMed @AdvaMedUpdate]

Medicare beneficiaries shouldn’t have to wait years for access to breakthrough medtech.

We joined 66 partners urging @CMSGov to create a clear, timely pathway so patients can access life-saving #medtech faster.

https://t.co/CKFw4XEN0g

[Joan Koerber-Walker @JKWinnovation]

Going to the @k4northwest Forum in Seattle on 8/21? Be sure to connect with Elsa Chi Abruzzo of @AnunciaInc . This award-winning Arizona #MedTech company is making a positive impact on the lives of people with #Hydrocephalis. https://t.co/VsnZd4Vxbj Follow
@ARAC100

[Joan Koerber-Walker @JKWinnovation]

From Boardrooms to Biotech: Joan Koerber-Walker on What Arizona’s Innovation Future Needs Part 1 https://t.co/wHx8PSaEXd

Thanks @wkyatv for supporting our Health Innovation Community!

[Joan Koerber-Walker @JKWinnovation]

From Startup Struggles to Saving Lives: Joan Koerber-Walker’s Playbook for Arizona’s Biotech Rise - Part 2
https://t.co/uvnEgeASsj
Thanks @wkyatv for a great conversation.

[Joan Koerber-Walker @JKWinnovation]

Arizona's bioscience sector is on the rise and our health innovations are making an impact. Arizona Leaders need to support this important industry and how misguided policies like Most Favored Nations (MFN) are not a good idea. https://t.co/9a2dAEMFce

[CSBI is LSWC @CSB_Institutes]

🚨 It's here! The 2025 Life Sciences Workforce Trends Report from X: @LifeSciWork highlights national trends in hiring, upskilling, AI, and STEM. Access the full report: 🔗 https://t.co/Dr77BWJbMr #LSWC2025 #BioJobs #FutureOfWork #LifeSciencesWorkforce

[Joan Koerber-Walker @JKWinnovation]

The Phoenix Bioscience Core is a place where unprecedented collaborations transpire between innovators and institutions of research excellence, setting a new standard in advancing precision medicine from discovery to delivery. #PHXisBIO
https://t.co/Ijyu9RkTIa

[Arizona Commerce Authority @azcommerce]

As part of Arizona’s @SelectUSA spinoff event, the ACA convened bioscience leaders to showcase our thriving industry ecosystem and opportunities for investment and entrepreneurs! Thank you to all who joined us and for sharing your insights.

[Joan Koerber-Walker @JKWinnovation]

Strategic investments and smart public policy can do more to reduce costs - and our overall federal debt - than cuts to what many Americans view as essential services. Health Innovation has the biggest potential for impact. Biotech CEO's - Check this out. https://t.co/BFYDjwfdHG

[Joan Koerber-Walker @JKWinnovation]

As NIH Cuts Loom, Research Organizations Need to Weigh Alternatives https://t.co/m1MUuYOWBm via @GENbio

[Joan Koerber-Walker @JKWinnovation]

Of Dogs and Diagnostics: Calviri is Focused on Early Detection and Vaccines for Both Canines and Their Human Companions https://t.co/bI2jVct8cY

[Joan Koerber-Walker @JKWinnovation]

Could it be possible to END CANCER instead of just treating it? Check out the AZAdvances Crypto Grand Challenge: Let's End Cancer! to learn more...
https://t.co/x8DkHzYs1f

#CryptoForGood

[Joan Koerber-Walker @JKWinnovation]

We need relevant measures of sophistication based on demonstrated competency that allow otherwise capable investors who don't meet those thresholds, especially in underserved communities and in middle America, to participate in wealth creation and support entrepreneurial ventures

[Joan Koerber-Walker @JKWinnovation]

America needs a strong clinical laboratory infrastructure to support the delivery of routine patient care! Help us #StopLabCuts to save patient care and the laboratory infrastructure by enacting SALSA: https://t.co/rmH9aiG1zY.

[Peter Kolchinsky @PeterKolchinsky]

Everyone in biotech should watch this Congressional testimony by three remarkable individuals.

Biotech CEOs Steve Potts (@DesertBiopharma) and John Crowley (@CONLEY15941395) defended the biomedical innovation ecosystem, advocated for the insurance reforms that are so essential to making medicines affordable, and pressed for a fix to the 9y small molecule penalty (change 9 to 13). They prepped, they he stood, and they spoke.

They were joined by the remarkable patient advocate John Czwartacki (@CZ), whose testimony, rooted in his own struggle with MS and appreciation of the power of innovation, is almost unparalleled by anything I've heard from anyone (@G17Esiason is in that zone). CZ made the point that we are all patients. He defended the power of the market to reveal what we all value... the pursuit of more and better life for everyone. He asked if the government can really be entrusted to be better than the market at calculating the value not only hope but real progress that transforms the lives of patients like him, like all of us.

It's also worth listening to the inventory of misunderstandings and misinformation that poured from the mouths of every single Democrat... except for Congressman @ScottPetersSD. He was the key leader in the House who stood in the way of HR3, which would have imposed price controls on all medicines at launch. I only wish that his own bill had passed instead of the IRA; he advocated for imposing price controls (Medicare Negotiation) after a drug had a patent-period of reward. Ultimately, his bill shifted HR3 from an extreme to the current "compromise" that gave biologics an adequate 13 years and small molecules a mere 9 years. And unlike any other Democrat who spoke at this hearing, he acknowledged that the IRA could and should be improved.

If only Democrats and Republicans could work together, there could be a majority that would pass the simple fix of changing 9 to 13 and keeping it budget neutral as Steve Potts proposed by just raising the minimum discount after 13 years (it's not like any investors assumes CMS will stick to the minimum discount anyways so the law may as well increase the discount so that the CBO can score those savings).

In the Senate, I think there would then be at least one Democratic Senator who would vote with Republicans to make that fix.

But President Biden would then need to sign it in. Imagine that... imagine a budget neutral fix to the IRA whose only effect was to restore incentives for small molecule innovation, taking more from old drugs to preserve incentives for new ones. Would President Biden shoot that down with a veto just because it was supported mostly by Republicans? Is he that spiteful? So arrogant about the perfection of this first draft of his landmark bill? I only hope we have the chance to find out.

@NPLB_org @IAmBiotech @PhRMA @SenateHELP @TheEconomist @WSJ @loopcoalition

[Joan Koerber-Walker @JKWinnovation]

Health innovation leaders are speaking up for patients and highlighting challenges created by the IRA. Learn more ...https://t.co/RICIQMw9rG @NPLB_org

[No Patient Left Behind @NPLB_org]

Affordability + Innovation. Now that's healthy synergy. Our new animation explains the importance of both when it comes to creating the medicines we need -- and how insurance needs to step up and do its part. Definitely worth a watch. https://t.co/bALTJZN895